clinical endpoint comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-06-05. Numbers and descriptions here follow the published literature rather than marketing material.
Lyophilized thymosin alpha-1 is generally stored at or below minus twenty degrees Celsius, protected from moisture and light. Short-term handling at ambient temperature is possible for dry powder, but reconstituted solutions degrade faster and are usually kept at two to eight degrees Celsius with a defined expiry of days rather than weeks. Repeated freeze-thaw cycles should be avoided because they promote aggregation and loss of potency. Exact limits depend on the formulation and should follow the supplier's documentation.
Identity and purity are normally assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and truncation products. Mass spectrometry confirms molecular mass and detects modifications such as deamidation or oxidation. Amino acid analysis and peptide mapping provide additional sequence-level confirmation. For research material, a certificate of analysis typically reports these results together with water content and counter-ion identity, since the lyophilized powder is often supplied as an acetate or trifluoroacetate salt.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
| Property | Value | Notes |
|---|---|---|
| Storage temperature, powder | -20 °C or lower | Protect from light and moisture |
| Storage temperature, reconstituted | 2-8 °C | Use within days |
| Purity testing | Reversed-phase HPLC | Separates truncation products |
| Mass confirmation | Mass spectrometry | Detects deamidation and oxidation |
| Common salt forms | Acetate or trifluoroacetate | Affects solubility and weighing |
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
The name itself causes confusion, because several unrelated thymic peptides share the thymosin label. Thymosin beta-4, for example, is a different molecule with different functions. Naming conventions in the literature also mix descriptive research terms with assigned nonproprietary names, so a reader should confirm which entity a given paper addresses. Clarifying that point is usually the first step in interpreting any claim about this peptide.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Identity and purity are normally confirmed by reversed-phase high-performance liquid chromatography and mass spectrometry. The expected mass for the acetylated 28-residue peptide is close to 3108 daltons, and a mass shift indicates a modification or truncation. Peptide mapping after enzymatic digestion can resolve sequence-level questions. Counter-ion content, water content, and residual solvents are separate quality attributes that a certificate of analysis may or may not report. Aggregation is monitored by size-exclusion chromatography when relevant.
Thymosin alpha-1 is supplied as a lyophilized powder in most research settings. The solid dissolves readily in water and in common aqueous buffers, and it is typically reconstituted shortly before use. Solutions are clear and colourless at ordinary working concentrations. Because the peptide is hygroscopic, weighing and reconstitution are usually performed with minimal exposure to ambient air. Aliquots are prepared to avoid repeated freeze-thaw cycles, and working solutions are kept cold.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Heat or ionizing irradiation can be used to kill the bacteria that cause decomposition. Heat is applied by cooking, blanching or microwave heating in a manner that pasteurizes or sterilizes fish products. Cooking or pasteurizing does not completely inactivate microorganisms and may need to be followed with refrigeration to preserve fish products and increase their shelf life. Sterilised products are stable at ambient temperatures up to 40 °C, but to ensure they remain sterilized they need packaging in metal cans or retortable pouches before the heat treatment.
A nuclear localization signal (NLS) is a target peptide that directs proteins to the nucleus and is often a unit consisting of five basic, positively charged amino acids. The NLS normally is located anywhere on the peptide chain. A nuclear export signal (NES) is a target peptide that directs proteins from the nucleus back to the cytosol. It often consists of several hydrophobic amino acids (often leucine) interspaced by 2-3 other amino acids. Many proteins are known to constantly shuttle between the cytosol and nucleus and these contain both NESs and NLSs.
Acne necrotica Acquired generalized hypertrichosis (acquired hypertrichosis lanuginosa, hypertrichosis lanuginosa acquisita) Acquired perforating dermatosis (acquired perforating collagenosis) Acrokeratosis paraneoplastica of Bazex (acrokeratosis neoplastica, Bazex syndrome) Acroosteolysis Acute paronychia Alopecia areata Alopecia neoplastica Anagen effluvium Androgenic alopecia (androgenetic alopecia) Anhidrosis (hypohidrosis) Anonychia Apparent leukonychia Beau's lines Blue nails Bromidrosis (apocrine bromhidrosis, fetid sweat, malodorous sweating, osmidrosis) Bubble hair deformity Central centrifugal cicatricial alopecia (follicular degeneration syndrome, pseudopelade of the central scalp) Chevron nail (herringbone nail) Chromhidrosis (colored sweat) Chronic paronychia Cicatricial alopecia Clubbing (drumstick fingers, Hippocratic fingers, watch-glass nails) Congenital onychodysplasia of the index fingers Disseminate and recurrent infundibulofolliculitis Erosive pustular dermatitis of the scalp (erosive pustular dermatosis of the scalp) Erythromelanosis follicularis faciei et colli Folliculitis decalvans Folliculitis nares perforans Fox–Fordyce disease Frontal fibrosing alopecia Generalized congenital hypertrichosis (congenital hypertrichosis lanuginosa) Generalized hyperhidrosis Graham-Little syndrome Granulosis rubra nasi Green nails Gustatory hyperhidrosis Hair casts (pseudonits) Hair follicle nevus (vellus hamartoma) Hairy palms and soles Half and half nails (Lindsay's nails) Hangnail Hapalonychia Hematidrosis Hirsutism Hook nail Hot comb alopecia Hypertrichosis cubiti (hairy elbow syndrome) Hypertrichosis simplex of the scalp Intermittent hair–follicle dystrophy Keratosis pilaris atrophicans Kinking hair (acquired progressive kinking) Koenen's tumor (Koenen's periungual fibroma, periungual fibroma) Koilonychia (spoon nails) Kyrle disease Leukonychia (white nails) Lichen planopilaris (acuminatus, follicular lichen planus, lichen planus follicularis, peripilaris) Lichen planus of the nails Lichen spinulosus (keratosis spinulosa) Lipedematous alopecia (lipedematous scalp) Localized acquired hypertrichosis Localized congenital hypertrichosis Longitudinal erythronychia Longitudinal melanonychia Loose anagen syndrome (loose anagen hair syndrome) Lupus erythematosus Madarosis Malalignment of the nail plate Male-pattern baldness Marie–Unna hereditary hypotrichosis (Marie–Unna hypotrichosis) Median nail dystrophy (dystrophia unguis mediana canaliformis, median canaliform dystrophy of Heller, solenonychia) Mees' lines Melanonychia Menkes kinky hair syndrome (kinky hair disease, Menkes disease) Monilethrix (beaded hair) Muehrcke's nails (Muehrcke's lines) Nail–patella syndrome (Fong syndrome, hereditary osteoonychodysplasia, HOOD syndrome) Neoplasms of the nailbed Nevoid hypertrichosis Noncicatricial alopecia Onychauxis Onychoatrophy Onychocryptosis (ingrown nail, unguis incarnatus) Onychogryphosis (ram's horn nails) Onycholysis Onychomadesis Onychomatricoma Onychophagia (nail biting) Onychophosis Onychoptosis defluvium (alopecia unguium) Onychorrhexis (brittle nails) Onychoschizia Onychotillomania Ophiasis Palmoplantar hyperhidrosis (emotional hyperhidrosis) Parakeratosis pustulosa Patterned acquired hypertrichosis Perforating folliculitis Pili annulati (ringed hair) Pili bifurcati Pili multigemini Pili pseudoannulati (pseudo pili annulati) Pili torti (twisted hairs) Pincer nails (omega nails, trumpet nails) Pityriasis amiantacea (tinea amiantacea) Platonychia Plica neuropathica (felted hair) Plummer's nail Premature greying of hair Prepubertal hypertrichosis Pressure alopecia (postoperative alopecia, pressure-induced alopecia) Pseudofolliculitis barbae (barber's itch, folliculitis barbae traumatica, razor bumps, scarring pseudofolliculitis of the beard, shave bumps) Pseudopelade of Brocq (alopecia cicatrisata) Psoriatic nails Pterygium inversum unguis (pterygium inversus unguis, ventral pterygium) Pterygium unguis (dorsal pterygium) Purpura of the nail bed Racquet nail (brachyonychia, nail en raquette, racquet thumb) Recurrent palmoplantar hidradenitis (idiopathic palmoplantar hidradenitis, idiopathic plantar hidradenitis, painful plantar erythema, palmoplantar eccrine hidradenitis, plantar panniculitis) Red lunulae Ross' syndrome Rubinstein–Taybi syndrome Setleis syndrome Shell nail syndrome Short anagen syndrome Splinter hemorrhage Spotted lunulae Staining of the nail plate Subungual hematoma Telogen effluvium Terry's nails Traction alopecia Traumatic alopecia Traumatic anserine folliculosis Triangular alopecia (temporal alopecia, temporal triangular alopecia) Trichomegaly Trichomycosis axillaris Trichorrhexis invaginata (bamboo hair) Trichorrhexis nodosa Trichostasis spinulosa Tufted folliculitis Tumor alopecia Twenty-nail dystrophy (sandpapered nails, trachyonychia) Uncombable hair syndrome (cheveux incoiffable, pili trianguli et canaliculi, spun-glass hair) Wooly hair nevus (woolly hair nevus) X-linked hypertrichosis
Sources: en.wikipedia.org
Good clinical laboratory practice (GCLP) is a GxP guideline for laboratory samples from clinical studies. Good clinical practice (GCP) does not define requirements for laboratories and good laboratory practice (GLP) focusses on pre-clinical analyses and not on human samples from clinical trials. The Research Quality Association (RQA) suggested in 2003 a guideline to close the gap. Later the World Health Organization and the British Medicines and Healthcare products Regulatory Agency issued their own versions of a GCLP guideline.
Relatively short fragments of DNA, RNA, and modified oligonucleotides are also synthesised by the solid-phase method. Although oligonucleotides can be synthesised in a flask, they are almost always synthesised on solid phase using a DNA/RNA synthesizer. For a more comprehensive review, see oligonucleotide synthesis. The method of choice is generally phosphoramidite chemistry, developed in the 1980s.
A study by Hutchinson and colleagues in 2011 corroborated the previous estimation methods in general, but their estimation of peak growth rates is significantly higher; it found that the "maximum growth rates for T. rex during the exponential stage are 1790 kg/year". Although these results were much higher than previous estimations, the authors noted that these results significantly lowered the great difference between its actual growth rate and the one which would be expected of an animal of its size. The sudden change in growth rate at the end of the growth spurt may indicate physical maturity, a hypothesis which is supported by the discovery of medullary tissue in the femur of a 16 to 20-year-old T. rex from Montana (MOR 1125, also known as B-rex). Medullary tissue is found only in female birds during ovulation, indicating that B-rex was of reproductive age. Further study indicates an age of 18 for this specimen. In 2016, it was finally confirmed by Mary Higby Schweitzer and Lindsay Zanno and colleagues that the soft tissue within the femur of MOR 1125 was medullary tissue. This also confirmed the identity of the specimen as a female. The discovery of medullary bone tissue within Tyrannosaurus may prove valuable in determining the sex of other dinosaur species in future examinations, as the chemical makeup of medullary tissue is unmistakable. Other tyrannosaurids exhibit extremely similar growth curves, although with lower growth rates corresponding to their lower adult sizes.
"Osteogenesis Imperfecta Overview". NIH Osteoporosis and Related Bone Diseases. National Resource Center, National Institutes of Health, U.S. Department of Health and Human Services. 8 May 2023. Archived from the original on 4 October 2017.
Sources: en.wikipedia.org
Dry lyophilized powder tolerates short ambient exposure during handling and shipping. Long-term room-temperature storage is not recommended because moisture uptake and slow degradation can occur over months. Storage at minus twenty degrees Celsius is the common practice for extended periods.
Typical entries list appearance, identity by mass spectrometry, purity by chromatography, water or moisture content, and residual counter-ion. Some certificates also report microbial limits and endotoxin for materials intended for laboratory use. The reported methods and acceptance ranges vary between suppliers.
The peptide is often supplied as an acetate or trifluoroacetate salt, and the counter-ion affects solubility, weight-per-mole calculations, and compatibility with cell assays. Trifluoroacetate can be undesirable in some biological experiments. Knowing the salt form is necessary for accurate concentration determination.
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.